semaglutide immunoassay cross-reactivity glp-1 Full article: Improving sensitivity and drug tolerance of assays for neutralizing anti-drug antibodies to and native Overcoming Analytical Challenges in Liraglutide

These innovative, FDA-approved weight-loss injections have transformed the way obesity is treated

If everything goes smoothly and no unexpected safety signals emerge, the earliest realistic timeline for retatrutide hitting the market is probably 2027, possibly stretching to 2028

After June 29, the FDA's trajectory toward a final rule on 503B exclusions accelerates, and the broader legal environment for compounded GLP-1 programs will be better defined

Access is currently through research programs or, in some cases, via licensed physicians prescribing through compounding pharmacies

When it comes to defining a healthy diet multiple guidelines fit the bill

Access to diabetes prevention programs varies across provinces